Skip to main content
PMC home page
Heart logoLink to Heart
. 2001 Aug;86(2):219–220. doi: 10.1136/heart.86.2.219a

Implementation of the NICE guidelines for the primary prevention of mortality from ventricular tachyarrhythmias: implications for UK electrophysiology centres; activity modelling from the UK-HEART study

N GALL, M KEARNEY, A ZAMAN, S O'NUNAIN, K FOX, A FLAPAN, J NOLAN
PMCID: PMC1729852  PMID: 11454850

Full Text

The Full Text of this article is available as a PDF (146.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson R. H., Ho S. Y., Brecker S. J. Anatomic basis of cross-sectional echocardiography. Heart. 2001 Jun;85(6):716–720. doi: 10.1136/heart.85.6.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berry C., Hamilton C. A., Brosnan M. J., Magill F. G., Berg G. A., McMurray J. J., Dominiczak A. F. Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation. 2000 May 9;101(18):2206–2212. doi: 10.1161/01.cir.101.18.2206. [DOI] [PubMed] [Google Scholar]
  3. Buxton A. E., Lee K. L., Fisher J. D., Josephson M. E., Prystowsky E. N., Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999 Dec 16;341(25):1882–1890. doi: 10.1056/NEJM199912163412503. [DOI] [PubMed] [Google Scholar]
  4. Chopra M., Beswick H., Clapperton M., Dargie H. J., Smith W. E., McMurray J. Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl-containing ACE inhibitors. J Cardiovasc Pharmacol. 1992 Mar;19(3):330–340. doi: 10.1097/00005344-199203000-00005. [DOI] [PubMed] [Google Scholar]
  5. Cowie M. R., Struthers A. D., Wood D. A., Coats A. J., Thompson S. G., Poole-Wilson P. A., Sutton G. C. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997 Nov 8;350(9088):1349–1353. doi: 10.1016/S0140-6736(97)06031-5. [DOI] [PubMed] [Google Scholar]
  6. Cowie M. R., Struthers A. D., Wood D. A., Coats A. J., Thompson S. G., Poole-Wilson P. A., Sutton G. C. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet. 1997 Nov 8;350(9088):1349–1353. doi: 10.1016/S0140-6736(97)06031-5. [DOI] [PubMed] [Google Scholar]
  7. Crown J., O'Leary M. The taxanes: an update. Lancet. 2000 Apr 1;355(9210):1176–1178. doi: 10.1016/S0140-6736(00)02074-2. [DOI] [PubMed] [Google Scholar]
  8. D'Ambrosio A., Patti G., Manzoli A., Sinagra G., Di Lenarda A., Silvestri F., Di Sciascio G. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart. 2001 May;85(5):499–504. doi: 10.1136/heart.85.5.499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Grossman W. Diastolic dysfunction in congestive heart failure. N Engl J Med. 1991 Nov 28;325(22):1557–1564. doi: 10.1056/NEJM199111283252206. [DOI] [PubMed] [Google Scholar]
  10. Guzik T. J., West N. E., Black E., McDonald D., Ratnatunga C., Pillai R., Channon K. M. Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ Res. 2000 May 12;86(9):E85–E90. doi: 10.1161/01.res.86.9.e85. [DOI] [PubMed] [Google Scholar]
  11. Hortobagyi G. N. Treatment of breast cancer. N Engl J Med. 1998 Oct 1;339(14):974–984. doi: 10.1056/NEJM199810013391407. [DOI] [PubMed] [Google Scholar]
  12. Huraux C., Makita T., Kurz S., Yamaguchi K., Szlam F., Tarpey M. M., Wilcox J. N., Harrison D. G., Levy J. H. Superoxide production, risk factors, and endothelium-dependent relaxations in human internal mammary arteries. Circulation. 1999 Jan 5;99(1):53–59. doi: 10.1161/01.cir.99.1.53. [DOI] [PubMed] [Google Scholar]
  13. Knight C. J. National Institute for Clinical Excellence guidance: too NICE to glycoprotein IIb/IIIa inhibitors? Heart. 2001 May;85(5):481–483. doi: 10.1136/heart.85.5.481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kolettis T. M., Saksena S. Prophylactic implantable cardioverter defibrillator therapy in high-risk patients with coronary artery disease. Am Heart J. 1994 Apr;127(4 Pt 2):1164–1170. doi: 10.1016/0002-8703(94)90105-8. [DOI] [PubMed] [Google Scholar]
  15. Malik I. S., Bhatia V. K., Kooner J. S. Cost effectiveness of ramipril treatment for cardiovascular risk reduction. Heart. 2001 May;85(5):539–543. doi: 10.1136/heart.85.5.539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. McDonagh T. A., Robb S. D., Murdoch D. R., Morton J. J., Ford I., Morrison C. E., Tunstall-Pedoe H., McMurray J. J., Dargie H. J. Biochemical detection of left-ventricular systolic dysfunction. Lancet. 1998 Jan 3;351(9095):9–13. doi: 10.1016/s0140-6736(97)03034-1. [DOI] [PubMed] [Google Scholar]
  17. McMurray J. J., Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart. 2000 May;83(5):596–602. doi: 10.1136/heart.83.5.596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. McMurray J., McLay J., Chopra M., Bridges A., Belch J. J. Evidence for enhanced free radical activity in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1990 May 15;65(18):1261–1262. doi: 10.1016/0002-9149(90)90985-a. [DOI] [PubMed] [Google Scholar]
  19. Moss A. J., Hall W. J., Cannom D. S., Daubert J. P., Higgins S. L., Klein H., Levine J. H., Saksena S., Waldo A. L., Wilber D. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996 Dec 26;335(26):1933–1940. doi: 10.1056/NEJM199612263352601. [DOI] [PubMed] [Google Scholar]
  20. Nielsen O. W., Hansen J. F., Hilden J., Larsen C. T., Svanegaard J. Risk assessment of left ventricular systolic dysfunction in primary care: cross sectional study evaluating a range of diagnostic tests. BMJ. 2000 Jan 22;320(7229):220–224. doi: 10.1136/bmj.320.7229.220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Nielsen O. W., Hilden J., Larsen C. T., Hansen J. F. Cross sectional study estimating prevalence of heart failure and left ventricular systolic dysfunction in community patients at risk. Heart. 2001 Aug;86(2):172–178. doi: 10.1136/heart.86.2.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Nolan J., Batin P. D., Andrews R., Lindsay S. J., Brooksby P., Mullen M., Baig W., Flapan A. D., Cowley A., Prescott R. J. Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation. 1998 Oct 13;98(15):1510–1516. doi: 10.1161/01.cir.98.15.1510. [DOI] [PubMed] [Google Scholar]
  23. Prati F., Arbustini E., Labellarte A., Dal Bello B., Sommariva L., Mallus M. T., Pagano A., Boccanelli A. Correlation between high frequency intravascular ultrasound and histomorphology in human coronary arteries. Heart. 2001 May;85(5):567–570. doi: 10.1136/heart.85.5.567. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Sanmuganathan P. S., Ghahramani P., Jackson P. R., Wallis E. J., Ramsay L. E. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 2001 Mar;85(3):265–271. doi: 10.1136/heart.85.3.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sato H., Nagai T., Kuppuswamy D., Narishige T., Koide M., Menick D. R., Cooper G., 4th Microtubule stabilization in pressure overload cardiac hypertrophy. J Cell Biol. 1997 Nov 17;139(4):963–973. doi: 10.1083/jcb.139.4.963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Struthers A. D. The diagnosis of heart failure. Heart. 2000 Sep;84(3):334–338. doi: 10.1136/heart.84.3.334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 Jan 20;342(3):145–153. doi: 10.1056/NEJM200001203420301. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES